CAPNetz - Kompetenznetzwerk ambulant erworbene Pneumonie: Strukturen und Ziele

T. Welte; R. Marre; N. Suttorp

doi:10.1055/s-2003-36635

Pneumologie, Table of Contents

Pneumologie 2003; 57(1): 34-41
DOI: 10.1055/s-2003-36635

Projektdarstellung

CAPNetz - Kompetenznetzwerk ambulant erworbene Pneumonie: Strukturen und Ziele

CAPNet-Network of Competence for Community Acquired Pneumonia: Structures and AimsT. Welte¹ , R. Marre¹ , N. Suttorp¹

¹CAPNetz Geschäftsstelle, Ulm

Ein besonderer Dank gilt Herrn Dr. med. Gunther Boenisch, der als freier Medizinjournalist wesentlich zur Fertigstellung dieses Artikels beigetragen hat.

Abstract

Zusammenfassung

Die ambulant erworbene Pneumonie (Community Acquired Pneumonia/CAP) ist auch in Deutschland eine Erkrankung mit hoher Morbidität und Mortalität. Trotz der Bedeutung der CAP fehlen hier zu Lande zuverlässige Daten zum Erregerspektrum, zur Resistenzsituation der Erreger, zum Verlauf der Erkrankung ebenso wie evidenzbasierte Therapieempfehlungen. Auch die Grundlagenforschung in diesem Bereich ist stark verbesserungswürdig. Das Bundesministerium für Bildung und Forschung (BMBF) hat diese Defizite erkannt und fördert deshalb seit 2002 CAPNetz, das Kompetenznetzwerk ambulant erworbene Pneumonie.

Abstract

Community Acquired Pneumonia (CAP) is a disease with high morbidity and mortality in Germany. Apart from the importance of CAP, no reliably data is available about infective germs, resistance of germs, course of the disease, or evidence based treatment. Also basic research should be improved in this field. The German State Ministry for Research (BMBF) has recognised these deficits and supports CAPNet, the network of competence for Community Acquired Pneumonia since 2002.

Full Text

References

Literatur

1 Osler W. Lobar pneumonia. In: The principles and practice of of medicine. Edinburgh & London: Young J, Pentland 1901: 126-129
2 Chanock R M, Dienes L, Eaton M D. Mycoplasma pneumoniae: proposed nomenclature for atypical pneumonia organism. Science. 1963; 140 662-669
3 Farr B M, Kaiser D L, Harrison B DW. et al . Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. Thorax. 1989; 44 1031-1035
4 Tew J, Calenoff L, Berlin B S. Bacterial or nonbacterial pneumonia: accuracy of radiographic diagnosis. Radiology. 1977; 124 607-612
5 Woodhead M, Torres A. Definition and classification of community-acquired and nosocomial pneumonias. Eur Respir Mon. 1997; 3 1-12
6 Escamilla R, Hermant C. Pneumonia in immunocompromised patients. Eur Respir Mon. 1997; 3 189-208
7 Pingleton S K, Fagon J Y, Leeper K V. Patient selection for clinical investigation of ventilator-associated pneumonia. Chest. 1992; 102 (Suppl. 1) 557S-564S
8 ERS Task Force Report . Guidelines for management of adult community-acquired lower respiratory tract infections. Eur Respir J. 1998; 11 986-991
9 Bartlett J G, Breiman R F, Mandell L A. et al . Community-acquired pneumonia in adults: Guidelines for management. Clin Infect Dis. 1998; 26 811-838
10 Lopez A D, Murray C C. The global burden of disease. Nat Med. 1998; 4 1241-1243
11 Center for Disease Control and Prevention . Premature deaths, monthly mortality and monthly physician contacts - United States. MMWR Morb Mortal Wkly Rep. 1997; 46 556
12 Marston B J, Plouffe J F, File T M. et al . Incidence of community acquired pneumonia requiring hospitalizations. Arch Intern Med. 1997; 157 1509-1518
13 Niederman M S, McCombs J S, Unger A N. et al . The cost of treating community-acquired pneumonia. Clin Ther. 1998; 20 820-837
14 Fine M J, Auble T E, Yealy D M. et al . A prediction rule to identify low-risk patients with community acquired pneumonia. N Engl J Med. 1997; 336 243-250
15 Marrie T J, Lau C Y, Wheeler S L. et al . A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA. 2000; 283 749-755
16 Fine M J, Smith M A, Carson C A. et al . Prognosis and outcome of patients with community acquired pneumonia. JAMA. 1996; 275 134-141
17 Dean N C, Silver M P, Bateman K A. et al . Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med. 2001; 110 451-457
18 Moroney J F, Fiore A E, Harrison L H. et al . Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis. 2001; 33 797-805
19 Reinert R R, Al-Lahham A, Lemperle M. et al . Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. J Antimicrob Chemother. 2002; 49 61-68
20 Priest P, Yudkin P, McNulty C. Antibacterial prescribing and antibacterial resistance in English general practice: cross sectional study. BMJ. 2001; 323 1037-1041
21 Ross J J, Worthington M G, Gorbach S L. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med. 2002; 347 65-67
22 Marrie T J, Peeling R W, Fine M J. Ambulatory patients with community acquired pneumonia, the frequency of atypical agents and clinical course. Am J Med. 1996; 101 508-515

Geschäftsstelle CAPNetz

Albert-Einstein-Allee 47

89069 Ulm